dichloroacetic acid has been researched along with Malignant Melanoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bakker, BM; de Jong, S; Evers, B; Jalving, M; Tiersma, JF | 1 |
| Fosam, A; Gaspar, RC; Halberstam, AA; Lee, WD; Leitner, BP; Li, Z; Perry, RJ; Rabinowitz, JD; Robles, B; Zhang, X; Zhu, W | 1 |
| Abildgaard, C; Basse, AL; Dahl, C; Guldberg, P; Ma, T | 1 |
| Dutta, SK; Ghosh, M; Saha, S | 1 |
| Caldas, R; Lopes, JM; Máximo, V; Pardal, J; Pópulo, H; Soares, P | 1 |
| Pereira, Rde S | 1 |
| Balayssac, S; Ballot, C; Bernaudin, M; Corazao-Rozas, P; Corroyer-Dulmont, A; de Lassalle, EM; Formstecher, P; Guerreschi, P; Jendoubi, M; Jonneaux, A; Kluza, J; Maboudou, P; Maire, C; Malet-Martino, M; Marchetti, P; Mortier, L; Polakowska, R; Touil, Y; Valable, S | 1 |
7 other study(ies) available for dichloroacetic acid and Malignant Melanoma
| Article | Year |
|---|---|
Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities.
Topics: Dichloroacetic Acid; Diclofenac; Glucose; Humans; Melanoma; Pyruvate Dehydrogenase Acetyl-Transferring Kinase | 2022 |
Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma.
Topics: Animals; Dichloroacetic Acid; Fatigue; Lactic Acid; Melanoma; Mice; Quality of Life | 2023 |
Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition.
Topics: Amino Acid Substitution; Cell Proliferation; Dichloroacetic Acid; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Glutamic Acid; Humans; Indoles; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Tumor Cells, Cultured; Valine; Vemurafenib | 2014 |
A potent tumoricidal co-drug 'Bet-CA'--an ester derivative of betulinic acid and dichloroacetate selectively and synergistically kills cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Betulinic Acid; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dichloroacetic Acid; Disease Models, Animal; Drug Synergism; Esters; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Melanoma; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mitochondria; NIH 3T3 Cells; Oxidative Stress; Pentacyclic Triterpenes; Reactive Oxygen Species; Triterpenes | 2015 |
Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Dichloroacetic Acid; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Middle Aged; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins B-raf; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Skin Neoplasms; Survival; TOR Serine-Threonine Kinases | 2015 |
Developing new anti-cancer drugs.
Topics: Acetates; Antineoplastic Agents; Dichloroacetic Acid; Drug Design; Drug Discovery; Drugs, Investigational; Humans; Melanoma; Models, Biological; Neoplasms; Skin Neoplasms | 2011 |
Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dichloroacetic Acid; Female; HL-60 Cells; Humans; Hydrazines; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Male; Melanoma; Mice; Mice, SCID; Middle Aged; Mitochondria; Oxidative Phosphorylation; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Reactive Oxygen Species; RNA Interference; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |